603351.SHG Nanjing Well Pharmaceutical Co Ltd
- Market cap
- CNY 3.71B
- P/E
- 23.6x
- P/B
- 2.02x
- ROE
- 8.7%
- Dividend yield
- 1.75%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603351.SHG undervalued?
Graham number603351.SHG trades 45.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nanjing Well Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Nanjing Well Pharmaceutical Co Ltd yet.
Nanjing Well Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nanjing Well Pharmaceutical Co Ltd
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China and internationally. The company offers excipients for injection, oral, and topical applications; and active pharmaceutical ingredients (API), such as polidocanol and polyethylene glycol 3350 API/polyethylene glycol 4000 API. It also provides biomaterial products; wat…
Full company profileNanjing Well Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nanjing Well Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 558M | 694M | 801M | 881M | 736M | 1.04B | 1.11B | 1.16B | 1.30B | 1.34B | 1.44B |
| Gross Profit | 206M | 220M | 230M | 281M | 223M | 280M | 300M | 313M | 358M | 380M | 402M |
| Operating Income | 110M | 126M | 128M | 157M | 119M | 120M | 113M | 122M | 172M | 188M | 204M |
| EBITDA | -6.65M | 155M | 165M | 193M | 158M | 166M | 189M | 205M | 293M | 316M | 199M |
| Net Income | 85.0M | 107M | 112M | 128M | 100M | 101M | 95.0M | 112M | 146M | 151M | 160M |
| EPS | 1.05 | 1.10 | 1.14 | 1.00 | 0.77 | 0.76 | 0.71 | 0.83 | 1.08 | 1.11 | 1.18 |
| Balance Sheet | |||||||||||
| Total Assets | 600M | 726M | 808M | 1.46B | 1.64B | 1.84B | 2.14B | 2.28B | 2.38B | 2.59B | 2.39B |
| Total Liabilities | 156M | 193M | 194M | 217M | 337M | 456M | 656M | 686M | 673M | 791M | 549M |
| Shareholders' Equity | 444M | 533M | 615M | 1.24B | 1.30B | 1.38B | 1.48B | 1.58B | 1.70B | 1.80B | 1.83B |
| Cash & Short-term Investments | 73.3M | 75.7M | 40.4M | 271M | 272M | 92.5M | 101M | 159M | 247M | 424M | 169M |
| Total Debt | 62.3M | 85.0M | 94.8M | 102M | 116M | 200M | 426M | 487M | 424M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 128M | 71.3M | 63.8M | 130M | 93.3M | -11.5M | 109M | 120M | 222M | 238M | - |
| Capital Expenditure | 69.3M | 63.4M | 76.9M | 121M | 282M | 236M | 234M | 73.1M | 51.5M | 52.2M | 85.9M |
| Free Cash Flow | 58.9M | 7.92M | -13.2M | 9.08M | -189M | -247M | -125M | 47.2M | 170M | 186M | 155M |
| Ratios | |||||||||||
| ROE | 19.2% | 20.2% | 18.2% | 10.3% | 7.7% | 7.3% | 6.4% | 7.1% | 8.6% | 8.4% | 8.7% |
| ROA | 14.2% | 14.8% | 13.8% | 8.8% | 6.1% | 5.5% | 4.4% | 4.9% | 6.1% | 5.8% | 6.7% |
| Net Profit Margin | 15.2% | 15.5% | 14.0% | 14.5% | 13.6% | 9.7% | 8.6% | 9.7% | 11.3% | 11.3% | 11.1% |
| Debt to Equity | 0.14x | 0.16x | 0.15x | 0.08x | 0.09x | 0.14x | 0.29x | 0.31x | 0.25x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nanjing Well Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.75%
- Forward dividend
- 0.60 CNY
- Payout ratio
- 43.0%
- Ex-dividend date
- Jun 5, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 64.9M | 0.48 | 43.0% |
| 2024 | CNY 55.5M | 0.41 | 37.9% |
| 2023 | CNY 53.4M | 0.40 | 47.6% |
| 2022 | CNY 40.6M | 0.30 | 42.8% |
| 2021 | CNY 39.2M | 0.29 | 38.7% |
| 2020 | CNY 42.0M | 0.32 | 41.8% |
| 2019 | CNY 40.0M | 0.31 | 31.2% |
| 2018 | CNY 30.0M | 0.31 | 26.8% |
| 2017 | CNY 21.4M | 0.22 | 19.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on May 27, 2020.
Who owns Nanjing Well Pharmaceutical Co Ltd
- Insiders 61.49%
- Institutions 5.46%
- Public & others 33.05%
- Shares outstanding 135M
- Free float 56.3M
Nanjing Well Pharmaceutical Co Ltd company profile
- Company name
- Nanjing Well Pharmaceutical Co Ltd
- Ticker
- 603351.SHG
- ISIN
- CNE100003JD4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 718
- Fiscal year end
- December
- Address
- Building 5, Xuzhuang Software Park, Nanjing, China, 210042
- Phone
- 86 25 8317 2922
- Website
- wellnj.com
About Nanjing Well Pharmaceutical Co Ltd
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China and internationally. The company offers excipients for injection, oral, and topical applications; and active pharmaceutical ingredients (API), such as polidocanol and polyethylene glycol 3350 API/polyethylene glycol 4000 API. It also provides biomaterial products; water-ethylene glycol fire resistant hydraulic fluid, biodegradable hydraulic fluid base oil, full synthetic hydraulic fluid and compressor base oil, vehicle air conditioning compressor base oil, ester base oil for refrigeration compressor, gear oil, gear oil synthetic ester additive, base oil, synthetic esters, additive of metal working oil, lubricity additive for metal working fluid, base oil and additives for rolling oil, ester type emulsifier, special emulsifier for knitting machine oil, self-emulsifying ester, polyether products, ether type nonionic surfactant, auxiliaries of POY and FDY, as well as base oil for grease, automotive engines, and transmissions. In addition, the company offers Yangzhou well and research institute products; and a-linolenic acid, methyl and ethyl linolenate, linoleic acid, methyl linoleate, ethyl linoleate, EPA ethyl ester, oleic acid, methyl and ethyl oleate, arachidonic acid, methyl arachidonate, arachidonic acid ethyl ester, DHA oil, nervonic acid, eicosenoic acid, palmitoleic acid, palmitoleic acid methyl ester, "-linolenic acid, and "-linolenic acid methyl and ethyl esters. The company was formerly known as Nanjing Well Pharmaceutical Co.,Ltd. and changed its name to Nanjing Well Pharmaceutical Group Co.,Ltd. in April 2020. Nanjing Well Pharmaceutical Group Co.,Ltd. was founded in 2000 and is based in Nanjing, China.
Nanjing Well Pharmaceutical Co Ltd management
6- Mr. Renrong WuChairman & CEO · born 1963
- Mr. Qunsong TangVP, Secretary of the Board of Directors & CFO · born 1967
- Mr. Zhengsong GaoDirector, VP & Chief Engineer · born 1965
- Mr. Xinguo ChenDirector & VP · born 1968
- Mr. Jianguo ZouVice President · born 1963
- Yi YangAccounting Supervisor